Moreover, a phase I study (NCT01109095) of a HER2 specific CAR-T cell treatment of 17 patients with glioblastoma reported a great tolerance to the CAR-T cells administered doses and a median overall survival (OS) of 11.1 months for 8 patients after treatment and 24.5 months after diagnosis. This evidence concerns the gene ERBB2 and glioblastoma.